Table 2 Unadjusted comparisons for hospital admission within two weeks of COVID testing and for overall 30-day mortality *.
Admitted (n = 1,040) | Not Admitted (n = 1,553) | P- value***** | Alive (n = 2,408) | Deceased (n = 186) | p-value***** | |
|---|---|---|---|---|---|---|
PPI usage** (n,%) | Active use: 286 (27.5%) Past use: 54 (5.2%) No use: 700 (67.3%) | Active use: 162 (10.4%) Past Use: 44 (2.8%) No use: 1,347 (86.7%) | < .0001 | Active use: 392 (16.3%) Past use: 87 (3.6%) No use: 1,929 (80.1%) | Active use: 56 (30.1%) Past Use: 11 (5.9%) No use: 119 (64%) | < .0001 |
Age, years (mean ± SD)** | 66.5 ± 17.2 | 43.4 ± 16.5 | < .0001 | 50.7 ± 19.4 | 77.7 ± 12.8 | < .0001 |
Gender (n,%) | 488 female (46.9%) 552 male (53.1%) | 820 female (52.8%) 733 male (47.2%) | .003 | 1,229 female (51%) 1,179 male (49%) | 80 female (43%) 106 male (57%) | .04 |
Race (n,%) | 677 white (65.1%) 363 non-white/other/did not answer (34.9%) | 817 white (52.6%) 736 non-white/other/did not answer (47.4%) | < .0001 | 1,352 white (56.1%) 1,056 non-white/other/did not answer (43.9%) | 143 white (76.9%) 43 non-white/other/did not answer (23.1%) | < .0001 |
BMI, kg/m2 (mean ± SD)** | 30.5 ± 8.4 | 30.9 ± 7.3 | .28 | 31.0 ± 8.1 | 28.3 ± 5.9 | < .0001 |
Diabetes (n,%) | 498 (47.9%) | 277 (14.6%) | < .0001 | 630 (26.2%) | 95 (51.1%) | < .0001 |
COPD** (n,%) | 227 (21.8%) | 39 (2.5%) | < .0001 | 201 (8.3%) | 65 (34.9%) | < .0001 |
Cardiovascular disease*** (n,%) | 448 (43.1%) | 109 (7%) | < .0001 | 445 (18.5%) | 113 (60.8%) | < .0001 |
Kidney disease (n,%) | 351 (33.8%) | 56 (3.6%) | < .0001 | 308 (12.8%) | 100 (53.8%) | < .0001 |
Cancer (n,%) | 177 (17%) | 70 (4.5%) | < .0001 | 190 (7.9%) | 57 (30.6%) | < .0001 |
Obesity**** (n,%) | 503 (48.4%) | 477 (30.7%) | < .0001 | 905 (37.6%) | 75 (40.3%) | .46 |
